These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 33105541)
41. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC). Raez LE; Brice K; Dumais K; Lopez-Cohen A; Wietecha D; Izquierdo PA; Santos ES; Powery HW Clin Lung Cancer; 2023 Mar; 24(2):120-129. PubMed ID: 36585341 [TBL] [Abstract][Full Text] [Related]
42. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995 [TBL] [Abstract][Full Text] [Related]
43. Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations. Devarakonda S; Sankararaman S; Herzog BH; Gold KA; Waqar SN; Ward JP; Raymond VM; Lanman RB; Chaudhuri AA; Owonikoko TK; Li BT; Poirier JT; Rudin CM; Govindan R; Morgensztern D Clin Cancer Res; 2019 Oct; 25(20):6119-6126. PubMed ID: 31300452 [TBL] [Abstract][Full Text] [Related]
44. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999 [TBL] [Abstract][Full Text] [Related]
45. Clinical Application of Genomic Profiling With Circulating Tumor DNA for Management of Advanced Non-Small-cell Lung Cancer in Asia. Loong HH; Raymond VM; Shiotsu Y; Chua DTT; Teo PML; Yung T; Skrzypczak S; Lanman RB; Mok TSK Clin Lung Cancer; 2018 Sep; 19(5):e601-e608. PubMed ID: 29807856 [TBL] [Abstract][Full Text] [Related]
46. From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC. Bordi P; Del Re M; Minari R; Rofi E; Buti S; Restante G; Squadrilli A; Crucitta S; Casartelli C; Gnetti L; Azzoni C; Bottarelli L; Petrini I; Cosenza A; Ferri L; Rapacchi E; Danesi R; Tiseo M Lung Cancer; 2019 May; 131():78-85. PubMed ID: 31027702 [TBL] [Abstract][Full Text] [Related]
47. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer. Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078 [TBL] [Abstract][Full Text] [Related]
48. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. Aggarwal C; Thompson JC; Black TA; Katz SI; Fan R; Yee SS; Chien AL; Evans TL; Bauml JM; Alley EW; Ciunci CA; Berman AT; Cohen RB; Lieberman DB; Majmundar KS; Savitch SL; Morrissette JJD; Hwang WT; Elenitoba-Johnson KSJ; Langer CJ; Carpenter EL JAMA Oncol; 2019 Feb; 5(2):173-180. PubMed ID: 30325992 [TBL] [Abstract][Full Text] [Related]
49. The role of circulating free DNA in the management of NSCLC. Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523 [TBL] [Abstract][Full Text] [Related]
51. Patient-centric thresholding of Cobas® EGFR mutation Test v2 for surveillance of EGFR-mutated metastatic non-small cell lung cancer. Claus J; De Smet D; Breyne J; Wesolowski J; Himpe U; Demedts I; Martens GA Sci Rep; 2024 Aug; 14(1):18191. PubMed ID: 39107402 [TBL] [Abstract][Full Text] [Related]
52. Circulating tumor DNA testing in advanced non-small cell lung cancer. Moding EJ; Diehn M; Wakelee HA Lung Cancer; 2018 May; 119():42-47. PubMed ID: 29656751 [TBL] [Abstract][Full Text] [Related]
53. The presence and variant allele fraction of EGFR mutations in ctDNA and development of resistance. O'Kane GM; Liu G; Stockley TL; Shabir M; Zhang T; Law JH; Le LW; Sacher A; Shepherd FA; Bradbury PA; Leighl NB Lung Cancer; 2019 May; 131():86-89. PubMed ID: 31027703 [TBL] [Abstract][Full Text] [Related]
54. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595 [TBL] [Abstract][Full Text] [Related]
55. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259 [TBL] [Abstract][Full Text] [Related]
56. Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer. Mao X; Zhang Z; Zheng X; Xie F; Duan F; Jiang L; Chuai S; Han-Zhang H; Han B; Sun J J Thorac Oncol; 2017 Apr; 12(4):663-672. PubMed ID: 28007624 [TBL] [Abstract][Full Text] [Related]
58. A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2. Park CK; Cho HJ; Choi YD; Oh IJ; Kim YC Cancer Res Treat; 2019 Apr; 51(2):777-787. PubMed ID: 30189719 [TBL] [Abstract][Full Text] [Related]